Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Advanced BRCA-mutated High-grade Ovarian Cancer
NCT07371104Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib in ovarian cancer (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 16 and Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Day 16. Started Apr 2026; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07371104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371104.